{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:39:41Z","timestamp":1789479581718,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T00:00:00Z","timestamp":1674950400000},"content-version":"am","delay-in-days":362,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000646","name":"JSPS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19H05556"],"award-info":[{"award-number":["19H05556"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K09517"],"award-info":[{"award-number":["20K09517"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.urolonc.2021.11.005","type":"journal-article","created":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T03:07:27Z","timestamp":1640833647000},"page":"64.e1-64.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study"],"prefix":"10.1016","volume":"40","author":[{"given":"Daichi","family":"Sasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0026-4079","authenticated-orcid":false,"given":"Shingo","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8187-7212","authenticated-orcid":false,"given":"Yoshiomi","family":"Hatayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumu","family":"Kusaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7104-0945","authenticated-orcid":false,"given":"Daisuke","family":"Noro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikazu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9450-0027","authenticated-orcid":false,"given":"Hiroyuki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiharu","family":"Okuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teppei","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Yoneyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3760-919X","authenticated-orcid":false,"given":"Masahiko","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikara","family":"Ohyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2021.11.005_bib0001","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. part ii-2020 update: treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.11.005_bib0002","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/cas.14722","article-title":"Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients","volume":"112","author":"Shiota","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.urolonc.2021.11.005_bib0003","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/iju.14568","article-title":"Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: a subgroup analysis of the phase III ARCHES study","volume":"28","author":"Iguchi","year":"2021","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2021.11.005_bib0004","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/iju.14447","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study","volume":"28","author":"Uemura","year":"2021","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2021.11.005_bib0005","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/iju.14605","article-title":"Dynamics of conditional survival and risk factors in androgen deprivation therapy for prostate cancer using a multi-institutional Japan-wide database","volume":"28","author":"Chikamatsu","year":"2021","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2021.11.005_bib0006","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2021.11.005_bib0007","doi-asserted-by":"crossref","first-page":"E81","DOI":"10.5489\/cuaj.7074","article-title":"Canadian urological association (CUA)-Canadian uro oncology group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC)","volume":"15","author":"Saad","year":"2021","journal-title":"Can Urol Assoc J. 2021"},{"key":"10.1016\/j.urolonc.2021.11.005_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2020.100311","article-title":"Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group","volume":"25","author":"Brown","year":"2020","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.urolonc.2021.11.005_bib0009","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2021.11.005_bib0010","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2021.11.005_bib0011","doi-asserted-by":"crossref","first-page":"9307","DOI":"10.2147\/CMAR.S213051","article-title":"Population-based analysis of the use of radium-223 for bone-metastatic castration-resistant prostate cancer in Ontario, and of factors associated with treatment completion and outcome","volume":"11","author":"Cheng","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.urolonc.2021.11.005_bib0012","doi-asserted-by":"crossref","first-page":"8579","DOI":"10.1002\/cam4.3459","article-title":"Dynamic changes of bone metastasis predict bone-predominant status to benefit from radium-223 dichloride for patients with castration-resistant prostate cancer","volume":"9","author":"Hashimoto","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.urolonc.2021.11.005_bib0013","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s10147-020-01850-3","volume":"26","author":"Uemura","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.11.005_bib0014","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41391-020-00271-7","article-title":"Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center","volume":"24","author":"McKay","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urolonc.2021.11.005_bib0015","unstructured":"European Medicines Agency (EMA)\/500948\/2018, 1\u20134, published 27 July 2018, URL https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/ema-restricts-use-prostate-cancer-medicine-xofigo_en.pdf."},{"key":"10.1016\/j.urolonc.2021.11.005_bib0016","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2217\/fon-2020-0039","article-title":"Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer","volume":"16","author":"Kuppen","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.urolonc.2021.11.005_bib0017","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/MNM.0000000000001325","article-title":"Radium-223 therapy for metastatic castration-resistant prostate cancer: survival benefit when used earlier in the treatment pathway","volume":"42","author":"Jarvis","year":"2021","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.urolonc.2021.11.005_bib0018","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1007\/s00259-019-4261-y","article-title":"Interim analysis of the REASSURE (Radium-223 alpha emitter agent in non-intervention safety study in mCRPC popUlation for long-teRm evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice","volume":"46","author":"Dizdarevic","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.urolonc.2021.11.005_bib0019","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s10147-020-01776-w","article-title":"Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases","volume":"26","author":"Yamamoto","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.11.005_bib0020","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.clon.2018.06.004","article-title":"Real-world outcomes and factors predicting survival and completion of radium 223 in metastatic castrate-resistant prostate cancer","volume":"30","author":"Parikh","year":"2018","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.urolonc.2021.11.005_bib0021","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/1097-0142(19880101)61:1<195::AID-CNCR2820610133>3.0.CO;2-Y","article-title":"Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan","volume":"61","author":"Soloway","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2021.11.005_bib0022","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/iju.14614","article-title":"Prognosis of patients with prostate cancer and bone metastasis from the Japanese prostatic cancer registry of standard hormonal and chemotherapy using bone scan index cohort study","volume":"28","author":"Nakajima","year":"2021","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2021.11.005_bib0023","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"key":"10.1016\/j.urolonc.2021.11.005_bib0024","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.clgc.2016.07.027","article-title":"Hematologic safety of radium-223 dichloride: baseline prognostic factors associated with myelosuppression in the ALSYMPCA trial","volume":"15","author":"Vogelzang","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2021.11.005_bib0025","first-page":"12","article-title":"The prognostic role of baseline metabolic tumor burden and systemic inflammation biomarkers in metastatic castration-resistant prostate cancer patients treated with radium-223: a proof of concept study","author":"Bauckneht","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.urolonc.2021.11.005_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2019.05.012","article-title":"Disease characteristics and completion of treatment in patients with metastatic castration-resistant prostate cancer treated with radium-223 in an international early access program","volume":"17","author":"Saad","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2021.11.005_bib0027","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1200\/JCO.2019.37.15_suppl.5007","article-title":"Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333\/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: an interim safety analysis","volume":"37","author":"Tombal","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.11.005_bib0028","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/onco.13949","article-title":"Radium-223 plus enzalutamide versus enzalutamide in metastatic castration-refractory prostate cancer: final safety and efficacy results","volume":"26","author":"Maughan","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.urolonc.2021.11.005_bib0029","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1001\/jamaoncol.2020.6353","article-title":"Association of osteonecrosis of the jaw with zoledronic acid treatment for bone metastases in patients with cancer","volume":"7","author":"Van Poznak","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2021.11.005_bib0030","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00774-020-01151-9","article-title":"Antiresorptive agent-related osteonecrosis of the jaw in prostate cancer patients with bone metastasis treated with bone-modifying agents","volume":"39","author":"Nakai","year":"2021","journal-title":"J Bone Miner Metab"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921005019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921005019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:22:56Z","timestamp":1761042176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143921005019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1078143921005019"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.11.005","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}